9:22 AM
Leo Group India
| ||
| Pharmaceutical Developer Durata Trades Up 8.1% Post-IPO Wall Street Journal By Lynn Cowan. Early-stage pharmaceutical developer Durata Therapeutics Inc. (DRTX) made modest early trading gains on Thursday, its first day as a public company. The company's stock opened at $10 a share on the Nasdaq, up 11% from its initial public ... See all stories on this topic » | ||
| Taro Board rejects Sun Pharma offer for complete acquisition Business Standard Israel based Taro Pharmaceutical Industries today said a special committee of its board has rejected an offer from Sun Pharmaceutical Industries to purchase its issued and outstanding shares not held by the Indian pharma firm due to inadequate price. See all stories on this topic » | ||
| Taro rejects Sun Pharma buyout bid Moneycontrol.com Thu, Jul 19, 2012 at 20:00. Taro rejects Sun Pharma buyout bid. Taro Pharmaceutical Industries has rejected a USD 367 million bid from Sun Pharmaceutical Industries for the one-third stake of the Israeli company it does not already own. Source: Reuters ... See all stories on this topic » | ||
| Cadila Healthcare inks pact with Somaxon for Silenor Myiris.com Under the settlement and license agreement, Cadila Healthcare (Q,N,C,F)* and Zydus Pharmaceuticals (USA), have the right to begin selling a generic version of Silenor 180 days after another party begins selling a generic version of Silenor in the United ... See all stories on this topic » | ||
| Somaxon Pharmaceuticals Announces Settlement of Silenor Patent Litigation ... MarketWatch (press release) Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded products and product candidates to treat important medical ... See all stories on this topic » | ||
| Anthera Pharmaceuticals and Peregrine Pharmaceuticals Set for Growth as ... MarketWatch (press release) Anthera Pharmaceuticals a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation and autoimmune disorders, recently announced the final set of clinical data from the Phase 2b PEARL-SC study in patients with ... See all stories on this topic » | ||
| Massive Botnet is Brought Down, Curtailing Flow of Pharmaceutical Spam PCWorld Massive Botnet is Brought Down, Curtailing Flow of Pharmaceutical Spam Researchers have already seen a payoff: Only 21505 Grum IP addresses are sending spam now, compared with 120000 IP addresses before the takedown. Mushaq believes the rest ... See all stories on this topic » | ||
| Phrixus Pharmaceuticals, Inc. Reports Positive Preclinical Results in Respiratory ... MarketWatch (press release) ANN ARBOR, MI, Jul 19, 2012 (MARKETWIRE via COMTEX) -- Phrixus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on innovative therapies for Duchenne muscular dystrophy (DMD) and heart failure, today announced that it has ... See all stories on this topic » | ||
| 3 Pharmaceutical Stocks Making Big Moves On Wednesday July 18th Seeking Alpha Supernus Pharmaceuticals (SUPN) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The company is developing several product candidates in neurology and ... See all stories on this topic » | ||
| The Franklin Institute Receives $2.5 Million Gift From Teva Pharmaceuticals MarketWatch (press release) The Franklin Institute has received a $2.5 million contribution from leading global pharmaceutical company Teva Pharmaceuticals to develop a signature innovative exhibit at the museum exploring neuroscience and the human brain, entitled Your Brain. See all stories on this topic » |
Tip: Use quotes ("like this") around a set of words in your query to match them exactly. Learn more.
Delete this alert.
Create another alert.
Manage your alerts.
0 comments:
Post a Comment